Robert L. Coleman

52.4k total citations · 11 hit papers
690 papers, 23.3k citations indexed

About

Robert L. Coleman is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Robert L. Coleman has authored 690 papers receiving a total of 23.3k indexed citations (citations by other indexed papers that have themselves been cited), including 371 papers in Reproductive Medicine, 266 papers in Oncology and 166 papers in Obstetrics and Gynecology. Recurrent topics in Robert L. Coleman's work include Ovarian cancer diagnosis and treatment (361 papers), Endometrial and Cervical Cancer Treatments (157 papers) and PARP inhibition in cancer therapy (135 papers). Robert L. Coleman is often cited by papers focused on Ovarian cancer diagnosis and treatment (361 papers), Endometrial and Cervical Cancer Treatments (157 papers) and PARP inhibition in cancer therapy (135 papers). Robert L. Coleman collaborates with scholars based in United States, United Kingdom and Italy. Robert L. Coleman's co-authors include Anil K. Sood, Gabriel Lopez‐Berestein, Brian M. Slomovitz, Bradley J. Monk, Pedro T. Ramírez, David M. Gershenson, Thomas J. Herzog, Maurie Markman, Bryan T. Hennessy and Alpa M. Nick and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Robert L. Coleman

660 papers receiving 22.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer

2018 1.1k citations Robert L. Coleman et al. profile →
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

2020 780 citations Robert L. Coleman et al. profile →
RNA interference in the clinic: challenges and future directions

2010 654 citations Robert L. Coleman, Gabriel Lopez‐Berestein et al. profile →
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

1997 532 citations Robert L. Coleman et al. Journal of Clinical Oncology profile →
Ovarian cancer

2009 511 citations Robert L. Coleman et al. profile →
Latest research and treatment of advanced-stage epithelial ovarian cancer

2013 408 citations Robert L. Coleman, Bradley J. Monk et al. profile →
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

2017 406 citations Robert L. Coleman, Joan L. Walker et al. profile →
Exploring and comparing adverse events between PARP inhibitors

2019 346 citations Anil K. Sood, Robert L. Coleman et al. profile →
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

2016 295 citations Robert L. Coleman et al. Journal of Clinical Oncology profile →
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline

2016 274 citations Robert L. Coleman et al. profile →
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

2023 220 citations Domenica Lorusso, Ana Oaknin et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Robert L. Coleman

Since Specialization

Citations

This map shows the geographic impact of Robert L. Coleman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Coleman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Coleman more than expected).

Fields of papers citing papers by Robert L. Coleman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Coleman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Coleman. The network helps show where Robert L. Coleman may publish in the future.

Co-authorship network of co-authors of Robert L. Coleman

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Coleman. A scholar is included among the top collaborators of Robert L. Coleman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Coleman. Robert L. Coleman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey 2023 ·Cancer Control ·Michael Richardson, Kristopher Attwood, Gabriella Smith, Su‐Ying Liang, (unknown), Krishnansu S. Tewari, Robert L. Coleman, Daniel S. Kapp, John K. Chan, Bradley J. Monk	6
2	2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma 2022 ·International Journal of Gynecological Cancer ·Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Léary, Robert W. Holloway, Margarita Amenedo, Peter C.C. Fong, Jeffrey C. Goh, David M. O’Malley, Sandra Goble, Lara Maloney, Jonathan A. Ledermann	16
3	Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer 2020 ·Molecular Cancer Therapeutics ·(unknown), Shaolin Ma, Anca Chelariu-Raicu, Carola Leuschner, Hector W. Alila, Sanghoon Lee, Robert L. Coleman, Anil K. Sood	15
4	GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition 2019 ·Molecular Cancer Therapeutics ·Shaolin Ma, Sunila Pradeep, Alejandro Villar‐Prados, Yunfei Wen, Emine Bayraktar, Lingegowda S. Mangala, (unknown), Sherry Y. Wu, Wei Hu, Cristian Rodriguez‐Aguayo, Carola Leuschner, Xiaoyan Liang, Prahlad T. Ram, Katharina Schlacher, Robert L. Coleman, Anil K. Sood	13
5	Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA) 2017 ·Molecular Cancer Therapeutics ·Michael J. Wagner, Rahul Mitra, Mark J. McArthur, Wallace B. Baze, (unknown), Sherry Y. Wu, Cristian Rodriguez‐Aguayo, Xinna Zhang, Robert L. Coleman, Gabriel Lopez‐Berestein, Anil K. Sood	101
6	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth 2016 ·Molecular Cancer Therapeutics ·Jie Huang, Wei Hu, Limin Hu, Rebecca A. Previs, Heather J. Dalton, (unknown), Yunjie Sun, Michael H. McGuire, Rajesha Rupaimoole, Archana S. Nagaraja, Yu Kang, Tao Liu, Alpa M. Nick, Nicholas B. Jennings, Robert L. Coleman, Robert B. Jaffe, Anil K. Sood	41
7	Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study 2016 ·Journal of Clinical Oncology ·Bradley J. Monk, Michael W. Sill, Joan L. Walker, Christopher J. Darus, Gregory P. Sutton, Krishnansu S. Tewari, Lainie P. Martin, Jeanne M. Schilder, Robert L. Coleman, Jai Balkissoon, Carol Aghajanian	60
8	PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer 2015 ·Molecular Cancer Therapeutics ·Duangmani Thanapprapasr, Rebecca A. Previs, Wei Hu, Cristina Ivan, Guillermo N. Armaiz-Peña, Piotr L. Dorniak, Jean M. Hansen, Rajesha Rupaimoole, Jie Huang, Heather J. Dalton, Rouba Ali‐Fehmi, Robert L. Coleman, Anil K. Sood	15
9	Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer 2015 ·Molecular Cancer Therapeutics ·Rebecca A. Previs, Guillermo N. Armaiz-Peña, Yvonne G. Lin, Ashley N. Davis, Sunila Pradeep, Heather J. Dalton, Jean M. Hansen, William M. Merritt, Alpa M. Nick, Robert R. Langley, Robert L. Coleman, Anil K. Sood	11
10	Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer 2014 ·Clinical Cancer Research ·Yunfei Wen, Whitney A. Spannuth Graybill, Rebecca A. Previs, Wei Hu, Cristina Ivan, Lingegowda S. Mangala, Behrouz Zand, Alpa M. Nick, Nicholas B. Jennings, Heather J. Dalton, Vasudha Sehgal, Prahlad T. Ram, Ju‐Seog Lee, Pablo E. Vivas‐Mejía, Robert L. Coleman, Anil K. Sood	53
11	Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer 2014 ·Clinical Cancer Research ·Ju‐Won Roh, Jie Huang, Wei Hu, Xiaoyun Yang, Nicholas B. Jennings, Vasudha Sehgal, Bo Hwa Sohn, Hee Dong Han, Sun Joo Lee, Duangmani Thanapprapasr, Justin Bottsford-Miller, Behrouz Zand, Heather J. Dalton, Rebecca A. Previs, Ashley N. Davis, Koji Matsuo, Ju‐Seog Lee, Prahlad T. Ram, Robert L. Coleman, Anil K. Sood	15
12	PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer 2013 ·Journal of Clinical Oncology ·R. Wendel Naumann, Robert L. Coleman, Robert A. Burger, Edward A. Sausville, E. Kutarska, Sharad Ghamande, Nashat Gabrail, Stephen DePasquale, Elżbieta Nowara, Lucy Gilbert, Robert H. Gersh, Michael Teneriello, Wael A. Harb, Panagiotis A. Konstantinopoulos, Richard T. Penson, James T. Symanowski, (unknown), Christopher P. Leamon, David Morgenstern, Richard A. Messmann	169
13	Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214) 2011 ·Journal of Clinical Oncology ·R. Timothy D. Oliver, Graham M. Mead, Gordon Rustin, Johnathan Joffe, Nina Aass, Robert L. Coleman, Rhian Gabe, Philip Pollock, Sally Stenning	178
14	Converging Evidence for Efficacy from Parallel EphB4-Targeted Approaches in Ovarian Carcinoma 2010 ·Molecular Cancer Therapeutics ·Whitney A. Spannuth, Lingegowda S. Mangala, Rebecca L. Stone, Amy R. Carroll, Masato Nishimura, Mian M.K. Shahzad, Sun‐Joo Lee, Myrthala Moreno‐Smith, Alpa M. Nick, Ren Liu, Nicholas B. Jennings, Yvonne G. Lin, William M. Merritt, Robert L. Coleman, Pablo E. Vivas‐Mejía, Yue Zhou, Valery Krasnoperov, Gabriel Lopez‐Berestein, Parkash S. Gill, Anil K. Sood	33
15	EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma 2010 ·Clinical Cancer Research ·Jeong‐Won Lee, Rebecca L. Stone, Sun Joo Lee, Eun Ji Nam, Ju‐Won Roh, Alpa M. Nick, Hee‐Dong Han, Mian M.K. Shahzad, Hye‐Sun Kim, Lingegowda S. Mangala, Nicholas B. Jennings, Shenlan Mao, John Gooya, Dowdy Jackson, Robert L. Coleman, Anil K. Sood	57
16	Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer 2010 ·Molecular Cancer Therapeutics ·William M. Merritt, Alpa M. Nick, Amy R. Carroll, Chunhua Lü, Koji Matsuo, Melissa Dumble, Nicholas Jennings, ShuYun Zhang, Yvonne G. Lin, Whitney A. Spannuth, Aparna A. Kamat, Rebecca L. Stone, Mian M.K. Shahzad, Robert L. Coleman, Rakesh Kumar, Anil K. Sood	47
17	Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth 2008 ·Clinical Cancer Research ·Yvonne G. Lin, Anand Immaneni, William M. Merritt, Lingegowda S. Mangala, Seung Wook Kim, Mian M.K. Shahzad, Yvonne T.M. Tsang, Guillermo N. Armaiz-Peña, Chunhua Lu, Aparna A. Kamat, Liz Y. Han, Whitney A. Spannuth, Alpa M. Nick, Charles N. Landen, Kwong‐Kwok Wong, Michael J. Gray, Robert L. Coleman, Diane C. Bodurka, William R. Brinkley, Anil K. Sood	51
18	Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer 2007 ·Cancer Research ·Aparna A. Kamat, Tae Jin Kim, Charles N. Landen, Chunhua Lu, Liz Y. Han, Yvonne G. Lin, William M. Merritt, Premal H. Thaker, David M. Gershenson, Farideh Z. Bischoff, John V. Heymach, Robert B. Jaffe, Robert L. Coleman, Anil K. Sood	113
19	Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma 2007 ·Cancer Research ·Chunhua Lü, Tomás Bonome, Yang Li, Aparna A. Kamat, Liz Y. Han, Rosemarie Schmandt, Robert L. Coleman, David M. Gershenson, Robert B. Jaffe, Michael J. Birrer, Anil K. Sood	149
20	Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma 2006 ·Cancer Research ·Liz Y. Han, Charles N. Landen, José G. Treviño, Jyotsnabaran Halder, Yvonne G. Lin, Aparna A. Kamat, Tae‐Jin Kim, William M. Merritt, Robert L. Coleman, David M. Gershenson, William C. Shakespeare, Yihan Wang, (unknown), Chester A. Metcalf, David C. Dalgarno, Tomi K. Sawyer, Gary E. Gallick, Anil K. Sood	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact